Sarepta Therapeutics Inc. (SRPT) Given “Underperform” Rating at Jefferies Group
Jefferies Group reaffirmed their underperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a research note issued to investors on Thursday morning. They currently have a $7.00 price target on the stock.
Several other equities analysts have also recently commented on SRPT. Oppenheimer Holdings Inc. reiterated a buy rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, July 17th. Piper Jaffray Cos. reissued a sell rating and set a $6.00 price target on shares of Sarepta Therapeutics in a research report on Saturday, June 4th. Robert W. Baird reissued an outperform rating and set a $23.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Vetr lowered Sarepta Therapeutics from a buy rating to a strong sell rating and set a $17.28 price target on the stock. in a research report on Wednesday, June 8th. Finally, Janney Montgomery Scott reissued a hold rating on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $51.01.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 55.73 on Thursday. The firm’s 50 day moving average is $28.17 and its 200 day moving average is $21.37. The stock’s market capitalization is $2.67 billion. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $56.80.
Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm posted ($0.87) earnings per share. On average, equities analysts predict that Sarepta Therapeutics will post ($4.98) earnings per share for the current fiscal year.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the transaction, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at $2,309,490. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.90% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas raised its position in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. acquired a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $154,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $211,000. National Planning Corp raised its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. Finally, First Allied Advisory Services Inc. raised its position in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the period. 72.09% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.